← Back to Search

Opioid Analgesic

Buprenorphine Maintained Patients for Acute Pain

Phase 1
Waitlist Available
Led By D. Andrew Tompkins, MD MHS
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 day per session
Awards & highlights

Study Summary

This trial is testing whether ketamine and hydromorphone can relieve pain in people with opioid addiction who are taking buprenorphine.

Eligible Conditions
  • Acute Pain
  • Opioid Use Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 day per session
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day per session for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
peak change in cold pressor tolerance
Secondary outcome measures
peak change in cold pressor threshold
peak change in conditioned pain modulation (CPM)
Other outcome measures
Peak Drug Liking Visual Analog Scale

Trial Design

1Treatment groups
Experimental Treatment
Group I: Buprenorphine Maintained PatientsExperimental Treatment3 Interventions
All participants will be maintained on buprenoprhine for the treatment of opioid use disorder. All participants will be exposed to all 8 study drug combinations
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebos
2019
Completed Phase 4
~2030
Ketamine
FDA approved

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,500 Previous Clinical Trials
15,236,470 Total Patients Enrolled
5 Trials studying Acute Pain
594 Patients Enrolled for Acute Pain
D. Andrew Tompkins, MD MHSPrincipal InvestigatorUniversity of California, San Francisco

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Apr 2025